Seres Therapeutics (NASDAQ:MCRB) Stock Rating Lowered by JPMorgan Chase & Co.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating in a research note issued on Thursday, Marketbeat reports.

A number of other equities analysts have also commented on the company. Chardan Capital reiterated a "buy" rating and issued a $1.25 price objective on shares of Seres Therapeutics in a research note on Wednesday, August 14th. Canaccord Genuity Group reiterated a "buy" rating and set a $10.00 price target on shares of Seres Therapeutics in a report on Friday, September 13th. Finally, StockNews.com downgraded shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday, August 13th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $5.08.

Seres Therapeutics Price Performance

MCRB traded down $0.05 on Thursday, hitting $0.71. The company had a trading volume of 2,978,168 shares, compared to its average volume of 4,461,983. The stock has a market cap of $107.54 million, a price-to-earnings ratio of -1.18 and a beta of 2.03. The company's fifty day moving average price is $0.89 and its 200 day moving average price is $0.91. Seres Therapeutics has a 1-year low of $0.54 and a 1-year high of $2.05.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.08. During the same quarter in the prior year, the company earned $0.36 EPS. On average, sell-side analysts forecast that Seres Therapeutics will post -0.95 EPS for the current year.

Insider Activity

In related news, insider Teresa L. Young sold 24,480 shares of the company's stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $1.08, for a total value of $26,438.40. Following the sale, the insider now owns 78,178 shares of the company's stock, valued at $84,432.24. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last 90 days, insiders sold 28,844 shares of company stock worth $30,104. 5.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Seres Therapeutics

Several institutional investors have recently bought and sold shares of MCRB. Vanguard Group Inc. raised its stake in Seres Therapeutics by 12.1% during the first quarter. Vanguard Group Inc. now owns 6,734,821 shares of the biotechnology company's stock worth $5,213,000 after acquiring an additional 729,514 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Seres Therapeutics during the 1st quarter worth about $39,000. Virtu Financial LLC bought a new position in Seres Therapeutics during the 1st quarter valued at about $73,000. Point72 DIFC Ltd acquired a new position in Seres Therapeutics in the second quarter valued at about $64,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Seres Therapeutics during the second quarter worth about $92,000. Institutional investors and hedge funds own 59.34% of the company's stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.